Lyell Immunopharma (LYEL) FCF Margin (2020 - 2026)
Lyell Immunopharma (LYEL) posted FCF Margin of 1929950.0% for Q1 2026, down 250.57% sequentially from 550516.67% in Q4 2025, and down 114576429.0% YoY from N/an in Q1 2025.
Lyell Immunopharma (LYEL) FCF Margin (2020 - 2026) Analysis & Trends
Lyell Immunopharma has reported FCF Margin for 7 years, with the latest figure at 1929950.0% in Q1 2026.
- Quarterly FCF Margin fell 114576429.0% year-over-year to 1929950.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 433903.23% (down 16408015.0% YoY) and the FY2025 annual result came in at 418900.0%, down 15244426.0% from the prior year.
- FCF Margin declined to 1929950.0% in Q1 2026 per LYEL's latest filing, from 550516.67% in the prior quarter.
- Over five years, FCF Margin peaked at 45.26% in Q4 2022 and troughed at 1929950.0% in Q1 2026.
- A 5-year average of 505406.79% and a median of 293184.62% in 2024 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2022 and 2023: FCF Margin slumped 177391633 bps in 2022, then surged 163391200 bps in 2023.
- Over 5 years, FCF Margin stood at 45.26% in 2022, then plunged by 736192 bps to 333223.08% in 2023, then slipped by 28 bps to 426963.64% in 2024, then retreated by 29 bps to 550516.67% in 2025, then sank by 251 bps to 1929950.0% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 1929950.0%, 550516.67%, and 187753.33% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Lyell Immunopharma | 326.39 Mn | 326.39 Mn | - | -851,875.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -851,875.00% |
| Mar 31, 2026 | -1,929,950.00% |
| Dec 31, 2025 | -550,516.67% |
| Sep 30, 2025 | -187,753.33% |
| Jun 30, 2025 | -433,962.50% |
| Mar 31, 2025 | -784,185.71% |
| Dec 31, 2024 | -426,963.64% |
| Sep 30, 2024 | -104,152.94% |
| Jun 30, 2024 | -293,184.62% |
| Mar 31, 2024 | -1,401,533.33% |
| Dec 31, 2023 | -333,223.08% |
| Sep 30, 2023 | -140,888.00% |
| Jun 30, 2023 | -148,496.30% |
| Mar 31, 2023 | -73,453.85% |
| Dec 31, 2022 | -45.26% |
| Sep 30, 2022 | -1,774,800.00% |
| Jun 30, 2022 | -133.68% |
| Mar 31, 2022 | -8,672.51% |
| Dec 31, 2021 | -3,305.63% |
| Sep 30, 2021 | -883.67% |